{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T21:23:07Z","timestamp":1780694587930,"version":"3.54.1"},"reference-count":13,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PPA"],"DOI":"10.2147\/ppa.s336155","type":"journal-article","created":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T10:30:06Z","timestamp":1641897006000},"page":"69-78","source":"Crossref","is-referenced-by-count":5,"title":["Experiences and Preferences of Opioid-Use-Disorder Patients Who Switched from Brand to Generic Buprenorphine\/Naloxone Films: A Case Series"],"prefix":"10.2147","volume":"Volume 16","author":[{"given":"Erica","family":"Cede\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambar","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaris","family":"Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4698-8021","authenticated-orcid":true,"given":"Kyle","family":"Melin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Roman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angel","family":"Gonzalez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5955-3449","authenticated-orcid":true,"given":"Jorge","family":"Duconge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5802-9381","authenticated-orcid":true,"given":"Darlene","family":"Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,1]]},"reference":[{"key":"ref1","unstructured":"US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment. Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: a treatment improvement protocol (TIP 40); 2004."},{"key":"ref2","unstructured":"Buprenorphine. Substance Abuse and Mental Health Services Administration (SAMHSA); May 14, 2021. Available from: https:\/\/www.samhsa.gov\/medication-assisted-treatment\/medications-counseling-related-conditions\/buprenorphine. Accessed June, 2021."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/ADM.0000000000000166","volume":"9","author":"Comer","year":"2015","journal-title":"J Addict Med"},{"key":"ref4","doi-asserted-by":"publisher","volume-title":"Medications for Opioid Use Disorder Save Lives","year":"2019","DOI":"10.17226\/25310"},{"key":"ref5","unstructured":"FDA approves first generic versions of Suboxone sublingual film, which may increase access to treatment for opioid dependence. Food and Drug Administration; June 14, 2018. Available from: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-generic-versions-suboxone-sublingual-film-which-may-increase-access-treatment. Accessed December 6, 2019."},{"key":"ref6","unstructured":"Office of Generic Drugs. Food and Drug Administration; 2021. Available from: https:\/\/www.fda.gov\/about-fda\/center-drug-evaluation-and-research-cder\/office-generic-drugs. Accessed December 21, 2021."},{"key":"ref7","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/10550887.2015.1136494","volume":"35","author":"Binder","year":"2016","journal-title":"J Addict Dis"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/adaw.32391","volume":"31","author":"Knopf","year":"2019","journal-title":"Alcohol Drug Abuse Weekly"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1017\/S1092852920000267","volume":"25","author":"Datt","year":"2020","journal-title":"CNS Spectr"},{"key":"ref10","first-page":"192","volume":"40","author":"Santiago","year":"2021","journal-title":"P R Health Sci J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/10550887.2016.1139427","volume":"35","author":"Campbell","year":"2016","journal-title":"J Addict Dis"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jsat.2017.05.010","volume":"79","author":"Hui","year":"2017","journal-title":"J Subst Abuse Treat"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.drugalcdep.2018.03.033","volume":"188","author":"Vanderkam","year":"2018","journal-title":"Drug Alcohol Depend"}],"container-title":["Patient Preference and Adherence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=77563","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=77563","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,11]],"date-time":"2022-01-11T10:30:15Z","timestamp":1641897015000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/experiences-and-preferences-of-opioid-use-disorder-patients-who-switch-peer-reviewed-fulltext-article-PPA"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":13,"URL":"https:\/\/doi.org\/10.2147\/ppa.s336155","relation":{},"ISSN":["1177-889X"],"issn-type":[{"value":"1177-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}